References from scientific journals

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.

Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, de Freitas CS, Cardoso Soares V, da Silva Gomes Dias S, Temerozo JR, Miranda MD, Matos AR, Bozza FA, Carels N, Alves CR, Siqueira MM, Bozza PT, Souza TML. Fintelman-Rodrigues N, et al. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00825-20. doi: 10.1128/AAC.00825-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32759267 Free PMC article.

However, limited evidence exists for other clinically approved antiretroviral protease inhibitors. Extensive use of atazanavir (ATV) as antiretroviral and previous evidence suggesting its bioavailability within the respiratory tract prompted us to study this molecule again …
However, limited evidence exists for other clinically approved antiretroviral protease inhibitors. Extensive use of atazanavir (ATV) …

Renal effects of novel antiretroviral drugs.

Milburn J, Jones R, Levy JB. Milburn J, et al. Nephrol Dial Transplant. 2017 Mar 1;32(3):434-439. doi: 10.1093/ndt/gfw064. Nephrol Dial Transplant. 2017. PMID: 27190354 Free PMC article. Review.

This brief review will look at the novel agents dolutegravir, raltegravir, elvitegravir, cobicistat, tenofovir alafenamide fumarate and atazanavir, all of which have been licensed relatively recently, and describe issues relevant to renal function, creatinine handling and …
This brief review will look at the novel agents dolutegravir, raltegravir, elvitegravir, cobicistat, tenofovir alafenamide fumarate and a …

COVID-19 & antiepileptic drugs: Should we pay attention?

Fırat O, Yalçın N, Demirkan K. Fırat O, et al. Seizure. 2020 Aug;80:240-241. doi: 10.1016/j.seizure.2020.07.005. Epub 2020 Jul 7. Seizure. 2020. PMID: 32663783 Free PMC article. No abstract available.


Atazanavir.

Orrick JJ, Steinhart CR. Orrick JJ, et al. Ann Pharmacother. 2004 Oct;38(10):1664-74. doi: 10.1345/aph.1D394. Epub 2004 Sep 7. Ann Pharmacother. 2004. PMID: 15353575 Review.

In ARV-experienced patients, atazanavir was inferior to lopinavir/ritonavir unless atazanavir was coadministered with low-dose ritonavir. ...Atazanavir resistance is likely when resistance to >/=3 PIs is present. ...
In ARV-experienced patients, atazanavir was inferior to lopinavir/ritonavir unless atazanavir was coadministered with low-dose …

Atazanavir.

Goldsmith DR, Perry CM. Goldsmith DR, et al. Drugs. 2003;63(16):1679-93; discussion 1694-5. doi: 10.2165/00003495-200363160-00003. Drugs. 2003. PMID: 12904086 Review.

Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ...Atazanavir has a pharmacokinetic profile that allows for once-daily oral administration. ...
Atazanavir is a novel azapeptide protease inhibitor with high specificity for, and activity against, HIV-1 protease. ...Atazanavir …

Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.

Mendonza A, Hanna I, Meyers D, Koo P, Neelakantham S, Zhu B, Majumdar T, Rebello S, Sunkara G, Chen J. Mendonza A, et al. J Clin Pharmacol. 2016 Mar;56(3):355-64. doi: 10.1002/jcph.595. Epub 2015 Nov 2. J Clin Pharmacol. 2016. PMID: 26189431 Clinical Trial.

However, the Cmax,ss and AUCtau,ss of pradigastat decreased by 31% (90%CI: 0.62-0.78) and 26% (0.67-0.82), respectively, when administered in combination with atazanavir. This magnitude of decrease in pradigastat steady-state exposure is not considered clinically relevant. …
However, the Cmax,ss and AUCtau,ss of pradigastat decreased by 31% (90%CI: 0.62-0.78) and 26% (0.67-0.82), respectively, when administered i …

Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.

Costagliola D, Potard V, Lang S, de Castro N, Cotte L, Duval X, Duvivier C, Grabar S, Mary-Krause M, Partisani M, Ronot-Bregigeon S, Simon A, Tattevin P, Weiss L, Zucman D, Katlama C, Raffi F, Boccara F. Costagliola D, et al. J Infect Dis. 2020 Feb 3;221(4):516-522. doi: 10.1093/infdis/jiz481. J Infect Dis. 2020. PMID: 31828320

BACKGROUND: The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reported an increased risk of cardiovascular diseases in people with human immunodeficiency virus who were exposed to darunavir (DRV) but not to atazanavir (ATV). Our objective was to evalu …
BACKGROUND: The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reported an increased risk of cardiovascular diseases in …

Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, Ravindran P, Xiao H, Keicher C, Hüser A, Krystal M, Dicker IB, Grasela D, Lataillade M. Hwang C, et al. Clin Infect Dis. 2017 Aug 1;65(3):442-452. doi: 10.1093/cid/cix239. Clin Infect Dis. 2017. PMID: 28369211 Free PMC article. Clinical Trial.

In part B, subtype B-infected subjects received 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without () ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days. ...
In part B, subtype B-infected subjects received 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without () ritonav …

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.

Robertson K, Maruff P, Ross LL, Wohl D, Small CB, Edelstein H, Shaefer MS. Robertson K, et al. J Neurovirol. 2019 Feb;25(1):22-31. doi: 10.1007/s13365-018-0680-y. Epub 2018 Oct 8. J Neurovirol. 2019. PMID: 30298202 Free PMC article. Clinical Trial.

The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to abacavir/lamivudine + atazanavir (ABC/3TC + ATV). ...
The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) …

Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.

Krishna G, Moton A, Ma L, Martinho M, Seiberling M, McLeod J. Krishna G, et al. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):437-44. doi: 10.1097/qai.0b013e3181acb51b. J Acquir Immune Defic Syndr. 2009. PMID: 19623694 Clinical Trial.

METHODS: A phase 1, open-label, randomized, crossover, drug interaction study was conducted to assess the pharmacokinetic effects of coadministration of posaconazole (400 mg twice daily), with atazanavir (ATV) (300 mg/d alone) and with ritonavir (100 mg/d) or with efaviren …
METHODS: A phase 1, open-label, randomized, crossover, drug interaction study was conducted to assess the pharmacokinetic effects of coadmin …